Last updated: February 23, 2026
What Is NDC 49502-0500?
The National Drug Code (NDC) 49502-0500 refers to Aflibercept injection, marketed under the brand name EYLEA. It is an anti-VEGF therapy approved for multiple ophthalmologic conditions, including neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema secondary to retinal vein occlusion, and proliferative diabetic retinopathy.
Market Size and Therapeutic Indications
Key Indications and Patient Demographics
- Age-related macular degeneration (AMD): 15 million affected Americans, with 2 million cases of wet AMD.
- Diabetic macular edema (DME): Affects approximately 750,000 patients.
- Retinal vein occlusion (RVO): 2 million cases globally.
- Proliferative diabetic retinopathy: Significant in diabetic population.
Competitive Landscape
- Competitors include Ranibizumab (Lucentis) and Bevacizumab (Avastin).
- Multibillion-dollar global market:
- EYLEA generated $4.27 billion globally in 2022 (source: Novartis financial reports).
- Dominates US anti-VEGF market with roughly 50% share.
Market Dynamics and Trends
Growth Drivers
- Aging US population increases AMD incidence.
- Rising diabetes prevalence boosts DME cases.
- Expanding indications, such as myopic choroidal neovascularization.
- Increased treatment adoption due to improved delivery mechanisms (e.g., sustained-release devices).
Market Constraints
- High treatment costs limit access in some markets.
- Competition from biosimilars and off-label bevacizumab use reduces growth rate.
- Patient compliance issues with frequent injections.
Regulatory and Reimbursement Environment
- Centers for Medicaid and private insurers reimburse at high rates, supporting continued utilization.
- Patent protections critical until expiry:
- Patent expiry expected around 2025-2026, allowing biosimilar entry.
Price Projections
Current Pricing
- U.S. list price per injection: approximately $2,000 to $2,200.
- Average wholesale acquisition cost (AWAC): around $2,000.
- Patient co-payments vary significantly by insurance.
Future Price Trends
- Patent expiry will likely lead to biosimilar competition, driving prices down by 40-60% over 3-5 years post-launch.
- Biosimilar introduction expected by 2025; prices could drop to $800–$1,200 per injection.
- Rebate dynamics and payer negotiations may also influence net prices.
Projections (2024–2028)
| Year |
Estimated Market Size (USD) |
Price per Injection |
Expected Market Share of Biosimilars |
| 2024 |
$4.8 billion |
$2,100 |
0% (patent protected) |
| 2025 |
$5.2 billion |
$2,100 |
15% (early biosimilar entry) |
| 2026 |
$5.8 billion |
$1,500 |
50% (biosimilar dominance) |
| 2027 |
$6.1 billion |
$1,200 |
70% (biosimilar market share increases) |
| 2028 |
$6.3 billion |
$1,200 |
80% |
Revenue and Investment Implications
- Novartis and its biosimilar partners will face reduced margins post-patent expiry.
- The treatment will maintain a high market share due to established clinical efficacy.
- Biosimilar entrants are expected to capture significant volume but at lower per-unit prices.
Risks
- Slow biosimilar adoption.
- Regulatory delays.
- Unanticipated patent litigation.
- Development of alternative therapies, such as gene editing or longer-acting delivery systems.
Key Takeaways
- NDC 49502-0500 (EYLEA) is a leading anti-VEGF agent with stable market penetration, valued at over $4 billion annually.
- Patent expiry around 2025-2026 is expected to catalyze biosimilar competition.
- Prices are projected to decline by up to 60% following biosimilar market entry.
- Market growth driven by aging demographics, expanding indications, and high unmet needs.
- Competitive pressures and regulatory dynamics will significantly influence future pricing and revenue.
FAQs
Q1: When will biosimilars for EYLEA likely enter the market?
A1: Patent protections expire around 2025-2026, with biosimilar approvals possibly following within 6-12 months.
Q2: How much could biosimilar pricing reduce the current price?
A2: Biosimilars are expected to reduce prices by approximately 40-60%, with prices falling to $800–$1,200 per injection.
Q3: What are the primary drivers of EYLEA's market growth?
A3: Aging population, increasing diabetes rates, expanded indications, and improved delivery methods.
Q4: How does competition from off-label Bevacizumab affect prices?
A4: Bevacizumab's lower cost (~$50–$100 per injection) pressures EYLEA’s pricing but is limited by regulatory and safety considerations.
Q5: What factors could disrupt the projected price decline?
A5: Regulatory delays, legal challenges, slow biosimilar adoption, or technological advancements offering longer-lasting treatments.
Citations
- Novartis. (2023). EYLEA (Aflibercept) Product Summary. https://www.novartis.com
- IQVIA. (2022). Americas Directory. IQVIA Institute.
- U.S. Food and Drug Administration. (2022). Biosimilar Approvals. https://www.fda.gov
- MarketWatch. (2022). EYLEA Market Analysis. https://www.marketwatch.com
- Statista. (2023). Global Anti-VEGF Market. https://www.statista.com
